Cerity Partners
ADMA icon

Cerity Partners’s ADMA Biologics ADMA Stock Holding History

Cerity Partners’s Portfolio ADMA Stock Details ADMA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$344K Sell
38,147
-4,167
-10% -$65.8K ﹤0.01% 2512
2025
Q4 		$772K Buy
42,314
+1,266
+3% +$21.3K ﹤0.01% 1836
2025
Q3 		$602K Sell
41,048
-7,524
-15% -$129K ﹤0.01% 1863
2025
Q2 		$884K Buy
48,572
+869
+2% +$17.7K ﹤0.01% 1576
2025
Q1 		$946K Buy
47,703
+4,575
+11% +$79.1K ﹤0.01% 1448
2024
Q4 		$762K Sell
43,128
-7,750
-15% -$146K ﹤0.01% 1544
2024
Q3 		$1.02M Buy
50,878
+30,637
+151% +$476K ﹤0.01% 1388
2024
Q2 		$226K Buy
20,241
+2,783
+16% +$23.3K ﹤0.01% 1968
2024
Q1 		$115K Buy
17,458
+7,458
+75% +$40.8K ﹤0.01% 2191
2023
Q4 		$45.2K Sell
10,000
-300
-3% -$1.11K ﹤0.01% 1817
2023
Q3 		$36.9K Buy
10,300
+300
+3% +$1.16K ﹤0.01% 1367
2023
Q2 		$36.9K Buy
+10,000
New +$37.1K ﹤0.01% 1587

Other funds holding ADMA

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $194B AUM 35% 1-Year Est. Return

Cerity Partners's ADMA Position: Q1 2026 in Review

Cerity Partners reduced its ADMA Biologics (ADMA) stake by 9.8% in Q1 2026, selling an estimated $65.8K and leaving 38,147 shares worth $344K. The position accounts for ﹤0.01% of the portfolio, ranked #2512.

Cerity Partners first reported a position in ADMA in Q2 2023 and has held it in 12 quarters since. The position peaked at $1.02M in Q3 2024. 356 funds tracked by Wall St. Rank hold ADMA as of Q1 2026.

  • Cerity Partners held 38,147 shares of ADMA Biologics worth $344K as of Q1 2026.
  • Cerity Partners sold 4,167 ADMA Biologics shares in Q1 2026, an estimated $65.8K.
  • ADMA Biologics made up ﹤0.01% of Cerity Partners's portfolio in Q1 2026, its #2512 holding.
  • Cerity Partners first reported a position in ADMA Biologics in Q2 2023 and has held it in 12 quarters since.
  • Cerity Partners's ADMA Biologics position peaked at $1.02M in Q3 2024.
  • 356 funds tracked by Wall St. Rank held ADMA Biologics as of Q1 2026.

Based on Cerity Partners's 13F filing for Q1 2026, filed 15 May 2026.